• Company
• Yungjin applies for approval of its Ofev generic
• by Hwang, Byung-woo Aug 23, 2024 06:17am

• Policy
• Ildong to continue oral 'GLP-1 receptor agonist' trial
• by Lee, Hye-Kyung Aug 22, 2024 05:55am

• Company
• Yuhan’s Leclaza enters US 6yrs after signing licensing deal
• by Chon, Seung-Hyun Aug 22, 2024 05:50am

• Company
• Bavencio shows clear benefit in urothelial cancer
• by Hwang, Byung-woo Aug 22, 2024 05:50am

• Company
• MET-targeting anticancer drug 'Tepmetko' prescribed at Big 5
• by Eo, Yun-Ho Aug 22, 2024 05:50am

• Policy
• Preferential pricing delayed for homegrown new drugs
• by Lee, Tak-Sun Aug 22, 2024 05:50am

• Policy
• Takeda receives P3T approval for TAK-861 in Korea
• by Lee, Hye-Kyung Aug 21, 2024 05:48am

• Company
• SCLC drug tarlatamab may soon be introduced in KOR
• by Eo, Yun-Ho Aug 21, 2024 05:48am

• Policy
• Orphan drug 'Jaypirca' for Mantle Cell Lymphoma wins nod
• by Lee, Hye-Kyung Aug 21, 2024 05:47am

• Policy
• Reevaluation of foreign drug price comparisons
• by Lee, Tak-Sun Aug 21, 2024 05:47am